am580

AM580 (Ro40-6055) is a synthetic small molecule that acts as a highly selective agonist of the retinoic acid receptor alpha (RARα). It was developed by Roche as a research tool and investigative agent for its ability to selectively activate RARα-mediated signaling pathways. AM580 has been studied primarily in preclinical and early clinical settings for its antiproliferative effects in cancer cell lines, particularly breast cancer cells. It induces gene expression changes such as upregulation of apolipoprotein D and promotes granulocyte differentiation via RARα activation. The compound's selectivity distinguishes it from other retinoids that may also target RARβ or RARγ receptors. Its development for therapeutic use was discontinued.

Other names

AM580AM-580AM 580